VAM
INSY

Visium Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Visium Asset Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,653
Closed -$490K – 1283
2015
Q2 		$490K Buy
+13,653
New +$425K 0.01% 652

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Visium Asset Management's INSY Position: Q3 2015 in Review

Visium Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q3 2015, closing a stake of 13,653 shares — an estimated $490K sold.

Visium Asset Management first reported a position in INSY in Q2 2015 and held it in 1 quarter. The position peaked at $490K in Q2 2015. 145 funds tracked by Wall St. Rank hold INSY as of Q3 2015.

  • Visium Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Visium Asset Management sold 13,653 Insys Therapeutics, Inc. shares in Q3 2015, an estimated $490K.
  • Visium Asset Management first reported a position in Insys Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Visium Asset Management's Insys Therapeutics, Inc. position peaked at $490K in Q2 2015.
  • 145 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.